The Impact of CYP2C19 Genotype on Clopidogrel Response and Clinical Outcomes in Coronary Artery Disease Patients: A Correlation with SYNTAX Score

BackgroundCYP2C19 polymorphism helps determine the reactivity of platelets in coronary artery disease. The impact of CYP2C19 genotype on clopidogrel response and clinical outcomes remains unclear. The SYNTAX score helps in determining the prognosis. MethodsTo test this, we enrolled more than 500 patients with ischemic heart disease. All the patients were on follow-up treatment of antiplatelets, clopidogrel and aspirin. We noted the CYP2C19 phenotype for cardiovascular events. ResultsThis study included 156 individuals with a mean age of 59.2 {+/-} 10.6 months and a median age of 60 months. Most patients were male (71.2%). The mean SYNTAX score was 26.1 {+/-} 11.3, with a median of 29. Among participants, 25.6% had dyslipidemia, 75.6% had hypertension, and 49.4% had diabetes; only 9.6% had a history of PCI. There was no significant difference in age, BMI, sex, or smoking status between the stable angina and acute coronary syndrome groups. However, dyslipidemia, diabetes, PCI history, and a higher mean SYNTAX score were significantly more common in the acute coronary syndrome group. Statistical significance was achieved for SYNTAX score (P<0.05). ConclusionThe SYNTAX score can be used to predict the complexity of CAD in patients. The greater the score, the greater the probability of CAD